Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2007

Idex Purchases Isolation Technologies in a $30M Transaction

  • Idex acquired column hardware and accessories developer Isolation Technologies for a cash consideration of $30 million. The company supplies to the HPLC market.

    The company will operate as part of Idex’ Sapphire Engineering business within its Health and Science Technologies segment. Isolation Technologies has annual revenues of approximately $11 million, according to Idex. The acquisition is expected to be accretive to Idex’ earnings in 2008.

    “Isolation Technologies fits Idex’ growth strategy exceptionally well and is an excellent addition to our Health and Science Technologies segment,” states Larry Kingsley, chairman and CEO. “The expansion of our Sapphire Engineering business will broaden our product offering, enhancing our ability to meet our customers’ needs in the growing global market for analytical, biotechnology, and diagnostic instrumentation solutions.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »